Netminder

NetMinder is a biotechnology company focused on developing novel therapeutics that target Neutrophil Extracellular Traps (NETs) to treat life-threatening conditions such as thrombosis and chronic inflammation. Originating from research at Boston Children's Hospital and Harvard University, the company's technology aims to prevent the formation of or dissolve existing NETs, which are known to drive clot formation and tissue damage. By modulating the activity of NETs, NetMinder seeks to provide safer and more effective alternatives to traditional anticoagulants. The company's pipeline includes agents designed to inhibit the enzymes responsible for NETosis, such as PAD4, as well as direct NET-degrading proteins.